Arseus, in an announcement, made public its acquisition of Freedom Pharmaceuticals. Freedom Pharma is one of the world's leading suppliers of pharmaceutical raw materials, excepients, and other independent compounds for pharmaceutical use in the United States.
In 2013, Freedom is forecasting to realize approximately US$25 million for the Tulsa, OK based firm. It is for this reason that Arseus, based out of Belgium, has sought to acquire the US company in order they can mix their versions of drugs for the market.
The terms of the acquisition was not disclosed during the announcement. What Arseus did reveal was that it paid 5.5 times the EBITDA of Freedom Pharmaceuticals.
This acquisition would strengthen the global position for the market for drug compounding. In this market, pharmacists would assemble medications and concoctions specifically tailored to the needs of their medical patients.
Jacob (Jake) Jackson, President of Freedom Pharmaceuticals said, "I am looking forward to combining forces with the Fagron Group. Fagron's global and rapidly expanding network offers great potential to roll out successful and unique products and concepts internationally. Our clients will benefit from an excellent range of more than 1.500 high quality products and services, and our employees will enjoy opportunities for further development in an international environment."
Join the Conversation